Assessment of the tumor-associated trypsin inhibitor (TATI) marker in patients with carcinoma of the uterine body 17 years after treatment.

On the basis of literature review, the structure of the tumor-associated trypsin inhibitor (TATI) marker and its usefulness in diagnosing and monitoring of various malignant neoplasms has been described. The authors' own experiences are presented stemming from evaluation of TATI levels in a group of 305 patients suffering from carcinoma of the uterine body, who were primarily operated and then subjected to supplementary therapy in the Center of Oncology in Warsaw, classified in accordance with the FIGO 1988 protocol in the years 1994-1995, and who were observed for 17 years after discontinuation of treatment. A statistical analysis of the level of the TATI marker was carried out in the group of patients with unfavorable prognostic factors, that is the presence of cancerous infiltration in the uterine body, also found in the parametrium, ovaries, as well as diagnosed metastases to the lymphatic nodes found on the basis of postoperative histopathological protocol. The marker was determined three to seven times in serum after each stage of supplementary treatment, and at the beginning of the follow-up. Strong significance and elevation of the TATI marker were affirmed for the mean of four initial collections in patients, who had a relapse or metastases within one month to 11 years after termination of therapy.

[Immunoglobulin skin and renal deposits in patients with IgA nephropathy and Schonlein-Henoch purpura]. / Zlogi immunoglobulin w skórze i nerkach dzieci chorych na nefropatie IgA i zespól Schönleina-Henocha.

Skin biopsy was performed in 17 of 27 children with IgA nephropathy (IgAN) and 45 of 62 children with Schönlein-Henoch purpura (SHP). Renal biopsy was done in all patients with IgAN and in 51 of 62 with SHP. There was no correlation between presentation of immunological deposits in skin and renal biopsy. Deposits of IgA with or without other deposits or other deposits without IgA were observed in different pathomorphological states. Correlation between IgA serum concentration and presentation of deposits in skin was not observed. Attention was drawn to the high proportion of negative results in skin biopsy.

IgA endomysium antibody in children with dermatitis herpetiformis treated with gluten-free diet.

The IgA antibody to endomysium of smooth muscle (IgA-EmA) was measured in 32 children with confirmed dermatitis herpetiformis who were eating gluten-free diets. One patient had IgA-EmA before treatment but had a negative test one month later while on the diet. Two so treated for less than one year still had antibody, but of seven children treated for more than one year with gluten-free diet, none had detectable antibody. It was present in 13 of 20 children not adhering to the prescribed diet. The antibody was absent in 4 children with linear IgA bullous dermatosis and 43 children with various skin and intestinal diseases. These findings correspond to those in adults with dermatitis herpetiformis and indicate that IgA-EmA is also a marker for gluten-sensitive enteropathy in children.